Navigation Links
Neuroblastoma Expert Reviews Progress and Challenges in Fighting,Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhood cancers are fortunately rare, but among them, neuroblastoma is a special case, accounting for 7 percent of all childhood cancers, but 15 percent of childhood cancer deaths. It typically occurs as a solid tumor in the abdomen, but also in the neck, chest, and pelvis, developing in the network of the body's sympathetic nervous system.

Neuroblastoma is what physicians call a heterogeneous disease; its name includes subtypes of disease that behave very differently. Some cases strike in infants, but spontaneously disappear with minimal treatment, while other cases in older children may be relentlessly aggressive from the start. So precisely defining a given patient's risk level can help oncologists design the best treatment, avoiding the twin pitfalls of undertreating or overtreating any given child.

Better treatments may be on the horizon, but better understanding of neuroblastoma's precise biology can guide physicians to the best choices among possible options.

John Maris, M.D., of The Children's Hospital of Philadelphia, describes the current status of neuroblastoma treatment and trends for the near future, in the June 23 issue of the British journal Lancet. Maris is among the world leaders in neuroblastoma research, with a lab holding tissue samples from 5,000 patients -- the world's largest sample collection for the disease.

In his paper, Maris reviews new approaches to treatments for a particularly challenging set of patients -- children whose neuroblastoma has relapsed in an aggressive form. One particular technique being used and studied at Children's Hospital employs radioactive isotopes that zero in on neuroblastoma cells to selectively kill those cells with radiation. Other tools include retinoids -- biological molecules that hone in on cancer cells, angiogenesis inhibitors that cut off a tumor's blood supply, and tyrosine kinase inhibitors that interrupt a critical step in the tumor's growth process.

"These approaches are targeted therapies -- aimed in highly selective ways at cancer cells, but sparing healthy cells," said Maris. "But in order to best guide us to the most appropriate treatments, we need greater understanding of the abnormal biological events that give rise to neuroblastoma." One crucial technique for identifying biological pathways is through studies of the gene mutations and variations involved in different types of neuroblastoma, and Maris's team is calling on the sophisticated gene-hunting facilities at the new Center for Applied Genomics at Children's Hospital to advance that knowledge.

"Our goal is to match the most appropriate treatment with precise molecular targets in biological pathways, so we can intervene to stop neuroblastoma in its tracks," said Maris.

Support for the paper was provided in part by the National Institutes of Health, the Children's Oncology Group, and a variety of private foundations and organizations. In addition to his position at Children's Hospital, Maris is on the faculty of the University of Pennsylvania School of Medicine. Maris's co-authors were Michael D. Hogarty, M.D., of The Children's Hospital of Philadelphia and the University of Pennsylvania School of Medicine; Rochelle Bagatell, M.D., of the University of Arizona Health Sciences Center and Steele Children's Research Center of Tucson, Ariz.; and Susan L. Cohn, M.D., of Comer Children's Hospital and the University of Chicago.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit

Contact: Rachel Salis-Silverman

Phone: (267) 426-6063


CONTACT: Rachel Salis-Silverman of The Children's Hospital ofPhiladelphia, +1-267-426-6063,

Web site:

Company News On-Call:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Reatas Synthetic Triterpenoids Profiled in Nature Reviews Cancer
5. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
6. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
7. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
8. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
9. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
10. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
11. Caelyx Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 23, 2016  Guerbet announced today that it has ... Horizon Award . One of 12 suppliers ... for its support of Premier members through exceptional local ... and commitment to lower costs. ... of our outstanding customer service from Premier," says ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):